Gastric Cancer-Epidemiologic and Clinical Aspects

Helicobacter

Volumn 19, Issue S1, 2014, Pages 32-37

  Venerito, Marino ^a   Nardone, Gerardo ^b   Selgrad, Michael ^a   Rokkas, Theodoros ^c   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c HENRY DUNANT HOSPITAL   (Greece)

Author keywords

Chemotherapy; Eradication; Follow up; Gastric cancer; Helicobacter pylori; Ramucirumab

Indexed keywords

ANTIINFECTIVE AGENT;

DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; MICROBIOLOGY; PHYSIOLOGY; STOMACH NEOPLASMS;

ANTI-BACTERIAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; STOMACH NEOPLASMS;

EID: 84906777617     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12164     Document Type: Review

References (21)

1. Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 2012;4:156-69.
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013. Available from http://globocan.iarc.fr.
3. Holster IL, Aarts MJ, Tjwa ET, Lemmens VE, Kuipers EJ. Trend breaks in incidence of noncardia gastric cancer in the Netherlands. Cancer Epidemiol. 2014;38:9-15.
4. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours, 7th edn. Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell, November 2009. ISBN: 978-1-4443-3241-4.
5. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, EUROCARE-5 Working Group, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol. 2014;15:23-34.
6. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 2014;50:1330-44.
7. Bertuccio P, Rosato V, Andreano A, Ferraroni M, Decarli A, Edefonti V, La Vecchia C. Dietary patterns and gastric cancer risk: a systematic review and meta-analysis. Ann Oncol 2013;24:1450-8.
8. Zhang Y, Weck MN, Schöttker B, Rothenbacher D, Brenner H. Gastric parietal cell antibodies, Helicobacter pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in Germany. Cancer Epidemiol Biomarkers Prev 2013;22:821-6.
9. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M; Japan Gast Study Group. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-7.
10. Maehata Y, Nakamura S, Fujisawa K, et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc 2012;75:39-46.
11. Bae SE, Jung HY, Kang J, et al. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol 2014;109:60-7.
12. Choi J, Kim SG, Yoon H, Im JP, Kim JS, Kim WH, Jung HC. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol. 2014;12:793-800.
13. Kato M, Nishida T, Yamamoto K, et al. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. Gut 2013t;62:1425-32.
14. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-9.
15. Wilke H, Van Cutsem E, Oh SC, et al. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). Presented at the 2014 Gastrointestinal Cancers Symposium. J Clin Oncol 2014;32, (supplement 3; abstract LBA7).
16. Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:481-9.
17. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:490-9.
18. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma. ClinicalTrials.gov Identifier: NCT01697072 [WWW document]. URL: http://www.clinicaltrials.gov/ct2/show/NCT01697072.
19. Davies M. New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res. 2014;6:63-75.
20. A Randomized, Open-label, Two-arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First-line Chemotherapy in Subjects With Unresectable Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer. ClinicalTrials.gov Identifier: NCT01585987. [WWW document]. URL: http://clinicaltrials.gov/ct2/show/NCT01585987.
21. A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors. ClinicalTrials.gov Identifier: NCT01928394. [WWW document]. URL: http://www.clinicaltrials.gov/ct2/show/NCT01928394.